Your shopping cart is currently empty

NP10679 is an orally available, selective, brain-penetrating, potent, and pH-sensitive N-methyl-D-aspartate (NMDA) receptor inhibitor of the GluN2B subunit.NP10679 inhibits histamine H1, hERG channels, and CYP enzymes, and may be useful in the study of epilepsy and ischemic stroke.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $293 | In Stock | In Stock | |
| 5 mg | $722 | In Stock | In Stock | |
| 10 mg | $987 | In Stock | In Stock | |
| 25 mg | $1,520 | In Stock | In Stock | |
| 50 mg | $1,980 | In Stock | In Stock | |
| 100 mg | $2,500 | In Stock | In Stock |
| Description | NP10679 is an orally available, selective, brain-penetrating, potent, and pH-sensitive N-methyl-D-aspartate (NMDA) receptor inhibitor of the GluN2B subunit.NP10679 inhibits histamine H1, hERG channels, and CYP enzymes, and may be useful in the study of epilepsy and ischemic stroke. |
| Targets&IC50 | α1D-adrenoceptor:0.495 μM (Ki), α1A-adrenoceptor:0.603 μM (Ki), α1A-adrenoceptor:0.154 μM, α1B-adrenoceptor:1.92 μM (Ki), H1 Receptor:0.073 μM, α2C-adrenoceptor:3.09 μM (Ki), H1 Receptor:0.04 μM (Ki) |
| In vitro | NP10679 is an NMDA receptor inhibitor containing GluN2B that is more effective than physiological pH. It exhibits inhibitory effects on 5-HT2A, α1A adrenergic receptor, H1 histamine receptor, and hERG channels[2]. |
| In vivo | In the Male C57BL/6 middle cerebral artery occlusion (MCAo) model of transient ischemia mice, NP10679 (2, 5, and 10 mg/kg; intraperitoneal injection; administered 15 minutes prior to transient ischemia) dose-dependently reduces infarct volumes, with an ED50 of 1 mg/kg[2]. |
| Molecular Weight | 449.47 |
| Formula | C23H26F3N3O3 |
| Cas No. | 2914889-88-4 |
| Smiles | O(C[C@@H](CN1CCN(CC1)C2=CC=C(C(F)(F)F)C=C2)O)C=3C=C4C(=CC3)NC(=O)CC4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (177.99 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.